Plasma matrix metalloproteinase 9 as biomarker of prostate cancer progression in Dunning (Copenhagen) rats

Prostate

Volumn 54, Issue 3, 2003, Pages 206-211

  Jung, Klaus ^a   Krell, Hans Willi ^b   Ortel, Bernhard ^c   Hasan, Tayyaba ^c   Römer, Andreas ^a   Schnorr, Dietmar ^a   Loening, Stefan A ^a   Lein, Michael ^a,c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

MatLyLu; Matrix metalloproteinases; MMP inhibitor; Prostate cancer

Indexed keywords

5 BIPHENYL 4 YL 5 [4 (NITROPHENYL)PIPERAZINE 1 YL]PYRIMIDINE 2,4,6 TRIONE; BIOLOGICAL MARKER; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; RO 28 2653; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INVASION; CONTROLLED STUDY; DENSITOMETRY; HYPERTHERMIA; LASER; MALE; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RAT; RAT STRAIN; WESTERN BLOTTING; ZYMOGRAPHY;

EID: 0037441381     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10183     Document Type: Article

References (26)

1. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: Biologic activity and clinical implications. J Clin Oncol 2000;18:1135-1149.
2. Wilson MJ, Kapoor S, Vogel MM, Sinha AA. Characterization of gelatin-degrading metalloproteinase activities of the Dunning rat prostate tumor grown in nude mice. Prostate 1991;19:237-250.
3. Wilson MJ, Sinha AA. Plasminogen activator and metalloprotease activities of Du-145, PC-3, and 1-LN-PC-3-1A human prostate tumors grown in nude mice: Correlation with tumor invasive behavior. Cell Mol Biol Res 1993;39:751-760.
4. Rabbani SA, Harakidas P, Guo Y, Steinman D, Davidsen SK, Morgan DW. Synthetic inhibitor of matrix metalloproteases decreases tumor growth and metastases in a syngeneic model of rat prostate cancer in vivo. Int J Cancer 2000;87:276-282.
5. Wang M, Fudge K, Rhim JS, Stearns ME. Cytokine regulation of the matrix metalloproteinases and their inhibitors in human papillomavirus-18 transformed human prostatic tumor cell lines. Oncol Res 1996;8:303-315.
6. Stearns ME, Wang M. Regulation of kinesin expression and type IV collagenase secretion in invasive human prostate PC-3 tumor sublines. Cancer Res 1991;51:5866-5875.
7. Stearns M, Stearns ME. Evidence for increased activated metalloproteinase 2 (MMP-2a) expression associated with human prostate cancer progression. Oncol Res 1996;8:69-75.
8. Still K, Robson CN, Autzen P, Robinson MC, Hamdy FC. Localization and quantification of mRNA for matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of matrix metalloproteinase-2 (TIMP-2) in human benign and malignant prostatic tissue. Prostate 2000;42:18-25.
9. Wood M, Fudge K, Mohler JL, Frost AR, Garcia F, Wang M, Stearns ME. In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer. Clin Exp Metastasis 1997;15:246-258.
10. Hamdy FC, Fadlon EJ, Cottam D, Lawry J, Thurrell W, Silcocks PB, Anderson JB, Williams JL, Rees RC. Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer 1994;69:177-182.
11. Upadhyay J, Shekarriz B, Nemeth JA, Dong Z, Cummings GD, Fridman R, Sakr W, Grignon DJ, Cher ML. Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human prostate: Change in cellular localization associated with high-grade prostatic intraepithelial neoplasia. Clin Cancer Res 1999;5:4105-4110.
12. Festuccia C, Bologna M, Vicentini C, Tacconelli A, Miano R, Violini S, Mackay AR. Increased matrix metalloproteinase-9 secretion in short-term tissue cultures of prostatic tumor cells. Int J Cancer 1996;69:386-393.
13. Lokeshwar BL, Selzer MG, Block NL, Gunja-Smith Z. Secretion of matrix metalloproteinases and their inhibitors (tissue inhibitor of metalloproteinases) by human prostate explant cultures: Reduced tissue inhibitor of metalloproteinase secretion by malignant tissues. Cancer Res 1993;53:4493-4498.
14. Stetler-Stevenson WG, Yu AE. Proteases in invasion: Matrix metalloproteinases. Semin Cancer Biol 2001;11:143-152.
15. Drummond AH, Beckett P, Brown PD, Bone EA, Davidson AH, Galloway WA, Gearing AJ, Huxley P, Laber D, McCourt M, Whittaker M, Wood LM, Wright A. Preclinical and clinical studies of MMP inhibitors in cancer. Ann NY Acad Sci 1999; 878:228-235.
16. Lucia MS, Bostwick DG, Bosland M, Cockett AT, Knapp DW, Leav I, Pollard M, Rinker-Schaeffer C, Shirai T, Watkins BA. Workgroup I: Rodent models of prostate cancer. Prostate 1998;36:49-55.
17. Lein M, Jung K, Ortel B, Stephan C, Rothaug W, Johannsen M, Deger S, Schnorr D, Loening S, Krell H-W. The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model. Oncogene 2002;21:2089-2096.
18. Zucker S, Hymowitz M, Conner C, Zarrabi HM, Hurewitz AN, Matrisian L, Boyd D, Nicolson G, Montana S. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann NY Acad Sci 1999;878:212-227.
19. Duivenvoorden WC, Hirte HW, Singh G. Quantification of matrix metalloproteinase activity in plasma of patients enrolled in a BAY 12-9566 phase I study. Int J Cancer 2001;91:857-862.
20. Isaacs JT, Isaacs WB, Feitz WF, Scheres J. Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate 1986;9:261-281.
21. Lein M, Koenig F, Misdraji J, McDougal WS, Jung K, Loening SA, Hasan T, Ortel B. Laser-induced hyperthermia in rat prostate cancer: Role of site of tumor implantation. Urology 2000;56:167-172.
22. Jung K, Lein M, Laube C, Lichtinghagen R. Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood. Clin Chim Acta 2001;314:241-244.
23. Jung K, Lein M, Ulbrich N, Rudolph B, Henke W, Schnorr D, Loening SA. Quantification of matrix metalloproteinases and tissue inhibitors of metalloproteinase in prostatic tissue: Analytical aspects. Prostate 1998;34:130-136.
24. Woessner JF. Quantification of matrix metalloproteinases in tissue samples. In: Barrett AJ, editor. Proteolytic enzymes: Aspartic and metallopeptidases. San Diego: Academic Press; 1995. p 510-528.
25. Stearns ME, Wang M. Type IV collagenase (M(r) 72,000) expression in human prostate: Benign and malignant tissue. Cancer Res 1993;53:878-883.
26. Boag AH, Young ID. Increased expression of the 72-kDa type IV collagenase in prostatic adenocarcinoma. Am J Pathol 1994;144: 585-591.